Biliary Tract Cancer: Useful in Certain Circumstances…For HER2-positive tumors...Trastuzumab + Pertuzumab

pertuzumab/trastuzumab (Phesgo) is accepted for restricted use within NHSScotland....In combination with chemotherapy in...the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence...In combination with docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.

MyPathway is a non-randomised, multicentre, open-label, phase 2a, multiple basket study. Patients aged 18 years and older with previously treated metastatic biliary tract cancers with HER2 amplification, HER2 overexpression, or both...received intravenous pertuzumab...plus trastuzumab...Median follow-up was 8·1 months (IQR 2·7–15·7). Nine of 39 patients achieved a partial response (objective response rate 23% [95% CI 11–39])....The response rate is promising for the initiation of randomised, controlled trials of pertuzumab plus trastuzumab in this patient population.